Rpp29 regulates histone H3.3 chromatin assembly through transcriptional mechanisms

Prashanth Krishna Shastrula15, ‡, Peder J. Lund11, Benjamin A. Garcia12, and Susan M. Janicki13

From the ‡Wistar Institute, Philadelphia, Pennsylvania 19104, the 1Department of Biological Sciences, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 19104, and the 2Epigenetics Institute, Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

The histone H3 variant H3.3 is a highly conserved and dynamic regulator of chromatin organization. Therefore, fully elucidating its nucleosome incorporation mechanisms is essential to understanding its functions in epigenetic inheritance. We previously identified the RNase P protein subunit, Rpp29, as a repressor of H3.3 chromatin assembly. Here, we use a biochemical assay to show that Rpp29 interacts with H3.3 through a sequence element in its own N terminus, and we identify a novel interaction with histone H2B at an adjacent site. The fact that archaean Rpp29 does not include this N-terminal region suggests that it evolved to regulate eukaryote-specific functions. Oncogenic H3.3 mutations alter the H3.3–Rpp29 interaction, which suggests that they could dysregulate Rpp29 function in chromatin assembly. We also used KNS42 cells, an H3.3(G34V) pediatric high-grade glioma cell line, to show that Rpp29 1) represses H3.3 incorporation into transcriptionally active protein-coding, rRNA, and tRNA genes; 2) represses mRNA, protein expression, and antisense RNA; and 3) represses euchromatic post-translational modifications (PTMs) and promotes heterochromatic PTM deposition (i.e. histone H3 Lys-9 trimethylation (H3K9me3) and H3.1/2/3K27me3). Notably, we also found that K27me2 is increased and K36me1 decreased on H3.3(G34V), which suggests that Gly-34 mutations dysregulate Lys-27 and Lys-36 methylation in cis. The fact that Rpp29 represses H3.3 chromatin assembly and sense and antisense RNA and promotes H3K9me3 and H3K27me3 suggests that Rpp29 regulates H3.3-mediated epigenetic mechanisms by processing a transcribed signal that recruits H3.3 to its incorporation sites.

The nucleosome, composed of ~147 bp of DNA wrapped around an octamer of histone proteins (H3, H4, H2A, and H2B), is the fundamental unit of chromatin (1). The N-terminal tails of the histones protrude from the nucleosome core and are the targets of numerous post-translational modifications (PTMs),4 which modulate nucleosome structure and recruit chromatin-regulatory factors (2). The bulk of the histones are expressed during S phase to package newly replicated DNA. However, histone variants are expressed throughout the cell cycle and incorporated into chromatin through replication-independent (RI) mechanisms. Histone H3.3 is a variant of the H3 histones that differs from canonical H3.1 and H3.2 by 5 and 4 amino acids, respectively. H3.3 has emerged as a dynamic and integral regulator of transcriptional activation (3–6) and silencing (7–9), DNA replication and repair (10, 11), and differentiation and nuclear reprogramming (12–14). Therefore, fully elucidating H3.3-regulatory mechanisms will provide essential insight into how chromatin organization regulates cellular identity and genome integrity.

Distinct chromatin assembly factors regulate H3.3 incorporation and histone PTM deposition at different genomic sites (1, 15). The H3.3-specific chaperone, DAXX, together with the chromatin-remodeling factor, ATRX, are required for H3.3 deposition and H3 lysine 9 trimethylation (H3K9me3) at heterochromatin (7, 9, 16, 17). In the absence of ATRX–DAXX–mediated H3.3 chromatin assembly, heterochromatin organization is impaired, and endogenous retroviruses and imprinted genes are derepressed (15, 18, 19). HIRA, which is a component of the HUCA complex that also includes CABIN1, UBN1, and Asfla, is required for H3.3 incorporation at geneic sites (7, 20). Although the promoters and enhancers of the most highly transcribed genes have the highest H3.3 turnover rates (21, 22), H3.3 incorporation is better correlated with RNA pol II engagement and/or sequence-specific transcription factor binding at these sites than transcription (23). Transcription is, however, required for H3.3 incorporation into gene bodies (21). HIRA is also required for Polycomb repressive complex 2 (PRC2)–mediated deposition of H3 lysine 27 trimethylation (H3K27me3) at bivalent genes in embryonic stem cells (24). Although HIRA deletion does not impact basal transcription, it dysregulates differentiation, which suggests

4 The abbreviations used are: PTM, post-translational modification; AS, antisense; S, sense; GCTB, giant cell tumor of the bone; HGG, high-grade glioma; H2B-BR, H2B-binding region; H3.3-BR, H3.3-binding region; PRC2, Polycomb repressive complex 2; qMS, quantitative MS; RI, replication-independent; RMRP, RNase MRP catalytic RNA; pol, polymerase; RPL, ribosomal protein-like; RNP, ribonucleoprotein; GST, glutathione S-transferase; aa, amino acids; YFP, yellow fluorescent protein; qPCR, quantitative PCR; qRT-PCR, quantitative RT-PCR; DIA, data-independent acquisition; H3, histone H3; K, lysine; me1, me2, and me3, mono-, di-, and trimethylation; ac, acetylation.
that H3.3 incorporation is required for developmental signals to be converted into epigenetically inherited gene expression programs (24).

H3.3’s essential role in development is also highlighted by the finding that point mutations drive pediatric high-grade gliomas (HGGs) and skeletal cancers (2, 25–27). These mutations are located at or near PTM sites in the H3.3 N-terminal tail. In ~80% of diffuse intrinsic pontine gliomas, lysine 27, in either H3.3 or the canonical H3.1, is converted to methionine (K27M). H3(K27M) inhibits EZH2, the H3 Lys-27 methyltransferase in PRC2, through a direct interaction with its active site, which globally decreases H3K27me3 (28–31). Similarly, Lys-36 is mutated to K36M in chondroblastoma (32) and blocks Lys-36 methyltransferases through a similar mechanism (33, 34). H3.3 glycine 34 is also mutated to either arginine or valine in hemispheric pediatric HGGs and to tryptophan or leucine in giant cell tumor of the bone (GCTB). Less is known about how the Gly-34 mutations promote tumorigenesis, but alterations in H3 Lys-36 methylation have been reported (30, 35–37). These results suggest that oncohistone H3.3s drive tumorigenesis by dysregulating the chromatin landscape during differentiation.

Although the identification of H3.3-specific chaperones has provided enormous insight into chromatin assembly and histone PTM deposition, H3.3 functions remain incompletely understood due in part to the difficulty of elucidating events that initiate nucleosome incorporation. To address this, we investigated H3.3 recruitment dynamics at an activated transgene array and determined that H3.3 accumulates with RNA and RNA-regulatory factors (38, 39). Specifically, we showed that H3.3 co-localizes with AS RNA (39) and the following RNA factors: RNase P protein subunits (Rpp29, Rpp21, and POP1); fibrillarin, an RNA methyltransferase; and RPL23a (ribosomal protein–like) (38). We also reported that Rpp29 depletion increases H3.3 chromatin deposition and sense (S) and AS RNA levels, which suggests that an RNase P variant represses H3.3 chromatin assembly and transcription. Consistent with our results, a recent study identified RNA proteins, including RPLs and splicing factors, as H3.3-interacting factors (40). This study also showed that H3.3(G34W) increases chromatin compaction and causes aberrant RNA processing. Taken together, these results support the hypothesis that H3.3 chromatin assembly is functionally integrated with RNA processing and suggest that dysregulation of these events contributes to tumorigenesis.

Here, we continue our investigation of Rpp29 function in H3.3 chromatin assembly. RNase P is an endoribonuclease found in all three domains of life as either a ribozyme-centered ribonucleoprotein (RNP) or a protein-only enzyme, which is essential for cleaving the S’ leader sequence from precursor tRNAs (41, 42). In its RNP form, RNase P is composed of a single catalytic RNA and up to nine protein subunits. The bacterial RNP includes one protein. Archaea have up to five proteins, two of which are homologous to Rpp29 and Rpp21. Eukaryotes also have an RNase P variant, RNase MRP, which shares many of the same protein subunits but has a distinct catalytic RNA (i.e. RMRP). It is thought that the catalytic RNA and subunit complexity of RNase P have been preserved through evolution because they have essential roles in processes other than tRNA cleavage (41). In support of this hypothesis, RNase P variants and subunits have been shown to regulate RNA pol I and III transcription sites (43–45); to degrade noncoding RNA, including AS transcripts, in yeast (46); to regulate piRNA and tRNA gene chromatin (47); and to promote homology-directed DNA double-strand break repair (i.e. catalytic RNA, Rpp21, and Rpp29) (48). It is not known whether H3.3 is involved in any of these noncanonical RNase P functions. However, the findings that Rpp29 and H3.3 regulate DNA repair (10, 11, 49–51) suggest the possibility of functional overlap.

Here, we report that Rpp29 interacts with H3.3 through its eucharyote-specific N terminus. We also identify a novel interaction between Rpp29 and histone H2B and show that the oncogenic H3.3 mutations alter the H3.3–Rpp29 interaction, which suggests that they could dysregulate Rpp29 function in chromatin assembly. We also use shRNA knockdowns to show that Rpp29 represses H3.3 deposition and AS RNA expression from RNA pol I, pol II, and pol III genes. Using quantitative MS (qMS), we show that Rpp29 impacts histone PTMs. Specifically, Rpp29 represses euchromatic PTMs and promotes heterochromatic PTMs (i.e. H3K9me3 and H3.1/2/3K27me3). Taken together, these results suggest that Rpp29 regulates H3.3-mediated epigenetic mechanisms by processing a transcribed signal that recruits H3.3 to its incorporation sites.

Results

H3.3 interacts with the eucharyote-specific N terminus of Rpp29

We previously reported that Rpp29 co-localizes with histone H3.3 at an activated transgene array (38). We also showed that Rpp29 interacts with the 63 N-terminal amino acids of H3.3 (H3.3-N-tail-αN, Fig. 1B). In this assay, we incubate bacterially expressed and purified GST-tagged H3.3 constructs with lysates from cells expressing YFP-Rpp29 (Fig. 1A). Rpp29 associates with WT H3.3 (H3.3-WT) but not GST (Fig. 1C), as detected by immunoblotting with a GFP antibody (Fig. 1C). Additionally, the H3.3–Rpp29 interaction is diminished by the conversion of one lysine and three arginine residues, in and around the αN helix, to alanine (H3.3–4PTM; Fig. 1B, red asterisks indicate the locations of the point mutations). This result suggests that the H3.3 αN helix plays an important role in mediating the Rpp29 interaction.

Here, we used this assay to identify the region of Rpp29 that interacts with H3.3-N-tail-αN (Fig. 1). Human Rpp29 is composed of 220 amino acids (Fig. 1A). The C terminus (green) is conserved in both archaea and eukaryotes, and the N terminus (red) is specific to eukaryotes. Deletion of the 58 C-terminal amino acids (Rpp29(1–162)) did not eliminate the interaction with H3.3, which indicates that this region is not required (Fig. 1C). Deletion of the 50 N-terminal amino acids of Rpp29 (Rpp29(50–220)) also did not eliminate the interaction. Deletion of 74 and 98 N-terminal amino acids (Rpp29(76–220)) did, however, prevent the association, which indicates that the H3.3-binding region (H3.3-BR) is between amino acids 51 and 73 (Fig. 1A). The location of the H3.3-BR in the eucharyote-specific N terminus of Rpp29 suggests that this region may have...
evolved to regulate functions other than pre-tRNA processing. We also note that Rpp29(50–220) interacts better with H3.3–4PTM, compared with full-length Rpp29 (Fig. 1C). It is possible that deleting the 50 amino acids N-terminally adjacent to the H3.3-BR alters its conformation in a way that increases its affinity for H3.3–4PTM.

**Rpp29 interacts with histone H2B**

We also used this binding assay to determine whether Rpp29 interacts with any of the other core histones. To do this, we expressed and purified the N-terminal tail α1-helices of H2A (40 aa), H2B (53 aa), and H4 (47 aa) as GST proteins (Fig. 1D).
Rpp29 regulates H3.3 through transcriptional mechanisms

and incubated them with lysates from cells expressing YFP-Rpp29. This analysis revealed that Rpp29 also interacts with H2B but not H2A and H4 (Fig. 1E). To identify the H2B-binding region (H2B-BR) in Rpp29, we incubated GST-H2B with the Rpp29 deletion constructs (Fig. 1F). Deletion of the first 98 but not the first 75 acids of Rpp29 eliminated their interaction. This result indicates that the H2B-BR is within amino acids 76–98. The location of the H2B-BR region C-terminally adjacent to the H3.3-BR suggests that H3.3 and H2B do not compete for binding to Rpp29 (Fig. 1A). Although we do not know the significance of the Rpp29–H2B interaction, it further supports a functional connection between Rpp29 and chromatin.

The oncogenic H3.3 mutations impact the Rpp29 interaction

Because the oncogenic H3.3 mutations are within the region that interacts with Rpp29 (Fig. 1G), we also wanted to evaluate their impact on the association. Therefore, we introduced them into the GST-H3.3-N-tail-αN construct and used the binding assay to evaluate their effects on the interaction with YFP-Rpp29 (Fig. 1H). Compared with WT H3.3, the K27M, G34W, and G34R mutations significantly increased the association, whereas G34R decreased it. Although G34V did not have a significant effect, valine is smaller and has different chemical properties compared with arginine, phenylalanine, and leucine. Therefore, its effect on the Rpp29 interaction may not be detectable in this assay. Taken together, these results suggest that the oncogenic mutations significantly impact the H3.3–Rpp29 interaction, which could affect Rpp29 function in H3.3 chromatin assembly.

Rpp29 represses H3.3 incorporation into transcriptionally active genes

We also previously reported that Rpp29 represses H3.3 incorporation into chromatin using both ChIP, at a DAXX-ATRX–regulated transgene array, and a high-salt extraction assay (38). To evaluate the effects of Rpp29 depletion on H3.3 deposition at endogenous genes, we knocked Rpp29 down in KNS42 cells, a pediatric HGG cell line that harbors the H3.3(G34V) mutation, and used ChIP to measure H3.3 incorporation into several genes previously reported to be highly up-regulated (i.e. DLX-5, DLX-6, and MYCN) (Fig. 2D) and down-regulated (i.e. MYT1 and DLKI) (Fig. S1G, 27, 35). As a negative control, we knocked down Rpp20, which is one of the RNase P subunits that did not co-localize with H3.3 at the activated transgene array (38). As a positive control, we knocked down HIRA, which is required for H3.3 incorporation into single-copy genes (7). Fig. 2A shows that all of the shRNAs significantly decreased their respective mRNAs compared with the nonsilencing control (pLKO). We also measured H3.3 (i.e. hH3F3A and hH3F3B) mRNA (Fig. 2B) and evaluated H3.3 and H3 (i.e. H3.1, H3.2, and H3.3) protein levels using immunoblotting (Fig. 2C) to confirm that they are not affected by the knockdowns. The H3.3 antibody specifically recognizes H3.3 but not H3.1 and H3.2 (Fig. S1A). It also recognizes H3.3(G34V) (Fig. S1B), which indicates that H3.3(G34V) will also be measured in the ChIP analyses in KNS42 cells.

Rpp29 depletion significantly increased H3.3 incorporation at the promoters and gene bodies of DLX-5, DLX-6, and MYCN (Fig. 2E), which indicates that it represses H3.3 deposition at transcriptionally active genes. In contrast, Rpp20 depletion did not significantly alter H3.3 incorporation, with the exception of an increase at exon 3 of DLX-6 (Fig. 2E). Because Rpp20 is a component of canonical RNase P, its depletion could indirectly increase H3.3 incorporation by decreasing the stability of the subunits that regulate H3.3 chromatin assembly. In contrast, HIRA depletion significantly decreased H3.3 levels at five of the six promoter and exon sites (Fig. 2E), which is consistent with reports that HIRA is required for H3.3 deposition at single-copy genes (7). Additionally, Rpp29 depletion did not alter HIRA levels (Fig. 2C), which indicates that the increase in H3.3 deposition (Fig. 2E) is not due to an increase in HIRA.

Rpp29 depletion in the ovarian cancer cell line OVCAR-3 (Fig. S1C) also increases H3.3 incorporation into active genes (i.e. DLX-5 and PAX-8) (Fig. S1, D and E), which further supports the conclusion that Rpp29 represses H3.3 chromatin assembly at endogenous genes. Notably, Rpp29 depletion did not affect H3.3 deposition at down-regulated and inactive genes in both KNS42 (i.e. MYT1 and DLKI) (27, 35) (Fig. S1, G and H) and OVCAR-3 cells (i.e. MYO-D) (Fig. S1, D and E). These results suggest that Rpp29 represses H3.3 chromatin assembly at active genes.

Because H3.3 is also incorporated into tRNA and rRNA genes (21, 52–54) and RNase P variants bind to RNA pol I and pol III transcription sites (43–45), we also evaluated the effects of Rpp29 depletion on H3.3 incorporation at mRNA repeats and a tRNA–leucine gene (Fig. S1, J and K). Indeed, Rpp29 knockdown significantly increased H3.3 incorporation at these sites (Fig. S1K). Taken together, these results suggest that a subcomplex of RNase P, which includes Rpp29, regulates H3.3 chromatin assembly at transcriptionally active RNA pol I, pol II, and pol III genes.

Rpp29 represses mRNA and protein expression

To determine whether the increases in H3.3 incorporation induced by Rpp29 depletion correlate with changes in gene expression, we measured DLX-5, DLX-6, and MYCN mRNA in Rpp29-knockdown cells (Fig. 2F). Compared with the nonsilencing control (pLKO), Rpp29 depletion increased mRNA levels ~2-fold. In contrast, Rpp20 and HIRA depletion did not significantly affect them (Fig. 2F). This suggests that Rpp29 represses transcription, which is consistent with our previous report that Rpp29 depletion increases expression of the S RNA from the transgene and that Rpp29 overexpression accelerates transgene chromatin compaction (38). The finding that HIRA depletion did not significantly alter mRNA levels is consistent with previous reports that HIRA and H3.3 are not essential for basal transcription in mouse ES cells (7, 19).

To determine whether the increase in mRNA induced by Rpp29 depletion correlates with an increase in protein expression, we immunoblotted lysates for MYCN (Fig. 2G). Indeed, compared with the controls, MYCN is increased in Rpp29-knockdown cells. Although it is possible that Rpp29 depletion indirectly increases H3.3 chromatin assembly and transcription by disrupting the canonical functions of RNase P and RNase
**Rpp29 regulates H3.3 through transcriptional mechanisms**

MRP in tRNA and rRNA processing, respectively, the increase in MYCN suggests that translation is not significantly impaired in Rpp29-knockdown cells.

**Rpp29 represses antisense RNA**

Our finding that Rpp29 depletion increases H3.3 incorporation at transcriptionally active genes suggests that Rpp29...
Rpp29 regulates H3.3 through transcriptional mechanisms

Rpp29 represses H3.3 chromatin assembly by regulating a transcriptional event. It was previously reported that noncoding RNA, including AS transcripts, accumulate in yeast with a mutation in the catalytic RNA subunit of RNase P (46). Additionally, we previously showed that H3.3 co-localizes with Rpp29 and AS RNA at an activated transgene array and that Rpp29 depletion increases both H3.3 accumulation and transgene AS RNA levels (38, 39). To determine the impact of Rpp29 depletion on AS RNA expressed from endogenous genes, we measured it using strand-specific qRT-PCR. Rpp29 knockdown elevated AS RNA levels at the transcriptionally active but not the down-regulated genes in both KNS42 and OVCAR-3 cells (Fig. 2H and Fig. S1, F, I, and L). Therefore, the increase in H3.3 incorporation induced by Rpp29 depletion correlates with increases in both S and AS RNA.

Rpp20 depletion did not affect AS RNA (Fig. 2H), consistent with the finding that it does not impact H3.3 chromatin incorporation (Fig. 2E) or mRNA levels (Fig. 2F). Notably, however, HIRA depletion increased AS RNA levels (Fig. 2H), which is consistent with reports that when components of the HIR complex are deleted in yeast, cryptic transcription increases (55, 56). Although we have not shown a direct interaction between AS RNA and Rpp29 in this study, our previous report that Rpp29 and H3.3 colocalize with AS RNA at the activated transgene array (38, 39) and our current finding that H3.3 deposition correlates with increased S and AS RNA expression in Rpp29-knockdown cells suggest that 1) H3.3 is recruited to its incorporation sites by RNA, and 2) Rpp29 represses H3.3 chromatin assembly through a currently unknown RNA-processing mechanism.

Rpp29 represses H3K36me3 and H3K4me3 at active genes

We also used ChIP to evaluate the effect of Rpp29 depletion on the deposition of H3K36me3, which is enriched in gene bodies, because a previous analysis in KNS42 cells indicated that it is elevated at DLX-5, DLX-6, and MYCN (35) (Fig. 3A). We also included H3K4me3 in this analysis because it is enriched at the promoters of active genes (57). Rpp29 depletion significantly increased both H3K36me3 (Fig. 3B) and H3K4me3 (Fig. 3C) levels. These results suggest that, in Rpp29-knockdown cells, the increases in H3.3 incorporation (Fig. 2E) and transcription (Fig. 2F) are accompanied by increased deposition of euchromatic PTMs.

Rpp29, but not Rpp29(75–220), restores repression of H3.3 chromatin assembly in Rpp29-knockdown cells

To confirm that the increase in H3.3 deposition in Rpp29-knockdown cells is due, directly, to Rpp29 depletion and that it is not an off-target effect of the shRNA, we measured H3.3 incorporation at the MYCN promoter and gene body after expressing shRNA-resistant FLAG-tagged Rpp29 constructs (Fig. 3, D and E). Immunoblots using α-FLAG and α-Rpp29 antibodies show expression of Rpp29 and Rpp29(75–220), which is deleted of the H3.3-BR (Fig. 1A), in knockdown cells (Fig. 3D). FLAG-Rpp29 significantly reduced H3.3 incorporation at both the promoter and gene body of MYCN (Fig. 3E). Similar trends were seen for H3K36me3. These results confirm that the increases in H3.3 and H3K36me3 deposition in Rpp29-knockdown cells are caused by Rpp29 depletion. The finding that Rpp29(75–220) cannot repress H3.3 and H3K36me3 deposition to the same extent as full-length Rpp29 (Fig. 3E) suggests that the N terminus, which includes the H3.3-BR, is essential for this function.

Rpp29 depletion alters global histone PTM levels

Evaluating histone PTM levels at specific genes by ChIP requires selection of a limited number of antibodies. Therefore, to determine the effects of Rpp29 depletion on all histone PTMs and variants (about 250 uniquely modified peptides from canonical and variant histones) in KNS42 cells, we used “one-shot gunshot” qMS, which identifies changes in both single and combinatorial PTMs with high sensitivity (58) (Fig. 4). The volcano plot shows the histone peptides with PTMs that are significantly decreased (left of y axis) and increased (right of y axis) in Rpp29-knockdown cells (Fig. 4A). Strikingly, Rpp29 depletion significantly increased the levels of unmodified peptides from several histones (i.e. H3, H4, and H2A) (Fig. 4B), which suggests that Rpp29 promotes PTM deposition and/or prevents PTM removal.

Rpp29 depletion changes histone H3 PTMs

Of interest, Rpp29 depletion significantly increased the levels of unmodified H3 peptides that include PTM sites regulated by H3.3-chromatin assembly (i.e. H3 Lys-9 and H3 Lys-27) (7, 15) (Fig. 4B). Therefore, we focused on analyzing the H3 histones. For these qMS studies, histones are digested with trypsin after first being propionylated, which restricts cleavage to sites C-terminal of arginine and produces the following H3 N-terminal tail peptides: 3–8 aa, 9–17 aa, 18–26 aa, and 27–40 aa. For the first three, it is not possible to distinguish H3.3 from H3.1 and H3.2 because their amino acid sequences are exactly the same. However, amino acid differences in the 27–40 aa peptides make it possible to evaluate the variants. We did not detect significant changes in the PTMs on the 3–8 aa peptide, including H3K4me3 (Fig. S2A), despite the increases detected by ChIP at selected genes (Fig. 3C). Because H3K4me3 is mainly enriched in the 5′ regions of active genes (57), it may not be possible to detect Rpp29-induced changes when analyzing the
Rpp29 regulates H3.3 through transcriptional mechanisms

A

DLX-5

DLX-6

MYCN

B

H3K36me3 ChIP (KNS42 cells)

C

H3K4me3 ChIP (KNS42 cells)

D

E

ChIP (KNS42 cells)

H3.3

H3K36me3

H3.3

H3K36me3

MYCN Promoter

MYCN Exon 4

α-Flag

α-Rpp29

α-GAPDH
Rpp29 regulates H3.3 through transcriptional mechanisms

Rpp29 depletion decreases H3K9me3

Coincident with the increase in unmodified H3 9–17 aa (Fig. 4B), Rpp29 depletion induced a significant increase in H3K14ac and decrease in H3K9me3 (Fig. 4C). The H3K14ac increase is consistent with our finding that Rpp29 depletion increases PTMs associated with active chromatin (i.e. H3K4me3 and H3K36me3; Fig. 3). The decrease in H3K9me3 suggests that Rpp29 promotes heterochromatic histone PTM deposition and/or maintenance.

Rpp29 depletion alters H3 Lys-27 and Lys-36 methylation

Because serine is substituted at amino acid 31 in H3.3 in place of alanine in H3.1/H3.2 (Fig. 5), it is possible to differentiate the 27–40 aa peptides of these variants using MS (Fig. 5). Similarly, H3.3(G34A) can be distinguished from WT H3.3. Fig. 5B shows that H3.1/H3.2 are ~10 times more abundant than H3.3 and H3.3(G34A). Of note, Rpp29 depletion decreased H3.1/H3.2 K27me3, a PTM enriched at the promoters of inactive genes (59) (Fig. 5C). It also increased K27me1 and K27ac, which are associated with active chromatin (60). These results are consistent with our finding that Rpp29 depletion decreases the heterochromatic PTM, H3K9me3, and increases euchromatic PTMs (Figs. 3 and 4C). Because PRC2 is responsible for depositing all H3K27 methylation states (60), these results suggest that Rpp29 regulates PRC2 activity.

Rpp29 depletion also significantly increased K36me1 and K36me2 on H3.1/H3.2 (Fig. 5D). The fact that H3K36me2 and H3K36me3 antagonize PRC2-mediated H3K27me3 but still permit K27me1 (61, 62) suggests that Rpp29 promotes H3K27me3 by repressing H3K36me2 (Fig. 5C). The increase in K36me2 also suggests that the activity of the H3K36-specific dimethylase, Ash1 (61) (Fig. 5D), which is a Trithorax group protein that antagonizes Polycomb silencing (63), is up-regulated in Rpp29-knockdown cells. Although significant changes in H3.1/H3.2 K36me3 were not detected (Fig. 5D), the increase in K27me1 (Fig. 5C) suggests that the activity of the H3 Lys-36 trimethylase, SETD2, is also up-regulated because it is known to promote H3K27me1 by inhibiting its conversion to H3K27me2 (60).

Although similar trends in Lys-27 and Lys-36 methylation were seen for H3.3 (Fig. 5, E and F), all of these changes were not significant, due, perhaps, to its lower levels in KNS42 cells (Fig. 5B). However, similar to H3.1/2, Rpp29 depletion significantly decreased H3.3K27me3 (Fig. 5E) and increased H3.3K36me1 (Fig. 5F). It also decreased the combinatorial PTMs, H3.3K27me3/K36me1 and H3.3K27me1/K36me3 (Fig. 5C). It was previously reported that K27me1 and K36me3 only coexist on H3.3 (60). Therefore, the decrease in H3.3K27me3 induced by Rpp29 depletion further supports the hypothesis that Rpp29 regulates H3.3-PRC2–mediated epigenetic mechanisms.

H3.3(G34V) dysregulates Lys-27 and Lys-36 methylation in cis

Rpp29 depletion did not induce significant changes in PTM deposition on the H3.3(G34V) 27–40 aa peptide (Fig. 6A) (data not shown). However, notably, H3.3(G34V) has significantly higher K27me1 and K27me2 and lower K36me1 compared with H3.3 (Fig. 6, B and C). This suggests that G34V directly impacts the modification of the adjacent Lys-27 and Lys-36 residues. This is consistent with a recent report that used immunoblotting to show that G34L and G34W increase K27me3 and decrease K36me2 and K36me3 in cis (37). G34V could increase K27me2 in cis by inhibiting its removal or preventing its conversion to K27me3. The decrease in K36me1 on the G34V peptide suggests that the mutation inhibits Lys-36 monomethylation. Because Lys-36 methylation antagonizes Lys-27 methylation (61, 62), G34V could also promote K27me2 by inhibiting Lys-36 methylation. This result is consistent with reports that the Gly-34 mutations impair Lys-36 methylation (30, 35, 36). Taken together, these results suggest that the H3.3 Gly-34 mutations dysregulate the post-translational modification of their adjacent Lys-27 and Lys-36 residues.

Discussion

The presence of RNase P in all three domains of life and the preservation of its RNP form attest to both its ancient origins and the theory that RNA served as both enzyme and genome in the "RNA world" (41, 64). Due to its presence throughout cellular evolution, it is possible that RNase P played a foundational role in genome evolution. As such, our finding that the RNase P protein subunit, Rpp29, regulates H3.3 chromatin assembly provides an important opportunity to gain insight into the genomic functions of RNase P.

To investigate Rpp29 function in H3.3-mediated chromatin regulation, we first determined that Rpp29 interacts with the H3.3 N terminus through a sequence element in its own N terminus. The fact that this N-terminal region is not present in archaeal Rpp29 suggests that it evolved to regulate a eukaryote-specific function. Of interest, most archaeal histones are only composed of the histone fold region; they lack the N-terminal extensions of the eukaryotic histones, where almost all of the PTMs are deposited (65). Therefore, it is possible that the N termini of Rpp29 and H3.3 co-evolved during the development of more complex gene-regulatory mechanisms. Our finding that Rpp29 depletion impacts histone PTM deposition supports this hypothesis. It will be interesting to determine whether the Rpp29 C terminus interacts with the H3.3 histone...
Figure 4. Rpp29 depletion alters global histone PTM levels. A, volcano plot showing histone PTMs significantly altered following Rpp29 depletion as detected by quantitative MS. B, comparison of changes in unmodified histone peptide levels in Rpp29 knockdown (shRpp29) and nonsilencing control (pLKO) cells. Error bars, S.D. p values were calculated using two-tailed unpaired t test: n = 5 experimental replicates using the means of triplicate measurements for each replicate (*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001). C, comparison of changes in PTM levels on 9–17 aa peptides of H3 histones (i.e. H3.1, H3.2, and H3.3) in Rpp29 knockdown (shRpp29) and nonsilencing control (pLKO) cells.

Rpp29 regulates H3.3 through transcriptional mechanisms.

J. Biol. Chem. (2018) 293(32) 12360–12377
Rpp29 regulates H3.3 through transcriptional mechanisms

J. Biol. Chem. (2018) 293(32) 12360 –12377

A

H3.1/H3.2  K S A P A T G V K K P H R
H3.3  K S A P S T G V K K P H R
H3.3 G34V  K S A P S T G V V K K P H R

B

Histone H3 (27-40) peptide

C

H3.1/H3.2  K S A P A T G V K K P H R

D

H3.1/H3.2  K S A P A T G V K K P H R

E

H3.3  K S A P S T G V K K P H R

F

H3.3  K S A P S T G V K K P H R

ASBMB

J. Biol. Chem. (2018) 293(32) 12360 –12377

12369
Rpp29 regulates H3.3 through transcriptional mechanisms

Additional studies are also needed to define the mechanism through which the H3.3 and Rpp29 N termini interact. Because we incubated bacterially expressed H3.3 with lysates from cells expressing YFP-Rpp29, we do not know whether their interaction is direct. As both proteins are basic, we hypothesize that a negatively charged factor, such as the RNase P or RNase MRP catalytic RNA (RPPH1 and RMRP, respectively), mediates their association. Previously, we were unable to co-localize either of these RNAs with Rpp29 and H3.3 at the transgene array using

Figure 5. Rpp29 depletion alters PTM levels on H3 27–40 aa peptides. A, sequence diagrams of the histone H3.1/H3.2, H3.3, and H3.3(G34V) 27–40 aa peptides. B, comparison of relative amounts of H3.1, H3.2, and H3.3 27–40 aa peptides in KNS42 cells calculated using chromatographic peak areas of peptides detected by qMS. Error bars, S.D. p values were calculated using two-tailed unpaired t test: n = 5 experimental replicates using the means of triplicate measurements for each replicate. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. C, comparison of PTM level differences at Lys-36 on the 27–40 aa peptides of H3.3 and H3.3(G34V). D, proposed model of the Rpp29 function in H3.3 chromatin assembly and epigenetic regulation.

Figure 6. G34V increases K27me2 and decreases K36me1 in cis. A, sequence diagrams of the histone H3.3 and H3.3(G34V) 27–40 aa peptides. B, comparison of changes in PTM levels at Lys-27 on the 27–40 aa peptides of H3.3 and H3.3(G34V). Error bars, S.D. p values were calculated using two-tailed unpaired t test: n = 5 experimental replicates using the means of triplicate measurements for each replicate. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. C, comparison of PTM level differences at Lys-36 on the 27–40 aa peptides of H3.3 and H3.3(G34V).
RNA FISH or to disrupt the H3.3–Rpp29 interaction using RNases that degrade single and dsRNA (38). However, these negative results do not rule out the possibility that RPPH1 or RMRP is a component of the Rpp29–H3.3 complex, as their conformations could make them inaccessible to RNA FISH probes and RNases. In the future, it will be necessary to evaluate these interactions using purified components.

Our finding that Rpp29 interacts with the N terminus of histone H2B through a region that is C-terminally adjacent to the H3.3–BR also supports our conclusion that an RNase P variant regulates chromatin. Future studies will be needed to determine the functional significance of their association and whether the H2B–Rpp29 interaction is direct or mediated by RNA. It will also be important to determine whether Rpp29 interacts with H3.3 and H2B in the context of the nucleosome or during the process of chromatin assembly. Our previous finding that the H3.3 N terminus (H3.3-N-tail–αN) co-localizes with Rpp29, RNA, and RNA proteins at the activated transgene array suggests that they interact upstream of H3.3 nucleosome deposition (38). This idea is also supported by our finding that the αN helix, which contacts DNA in the nucleosome (66), is important for the H3.3–Rpp29 interaction (38). Understanding the timing of the Rpp29–H3.3 and –H2B interactions could also provide insight into whether Rpp29 regulates the establishment or maintenance of histone PTM patterns.

We also determined that Rpp29 represses H3.3 incorporation into the promoters and gene bodies of endogenous transcriptionally active genes, specifically single-copy protein-coding as well as rRNA and tRNA genes, but not inactive genes. The finding that the increase in H3.3 incorporation at active genes correlates with an increase in AS RNA suggests a regulatory relationship between noncoding RNA and H3.3 chromatin assembly. It was previously reported that in yeast, cryptic transcription increases when RI chromatin assembly factors, including HIRA homologs, are deleted (55, 56). It is thought that loss of chromatin structure grants the transcription machinery access to cryptic promoters (67, 68). Our finding that HIRA depletion both decreases H3.3 incorporation and increases AS RNA supports this idea. However, our finding that Rpp29 depletion increases both H3.3 incorporation and AS RNA suggests that RNA-processing events are also required to repress cryptic transcripts. This idea is supported by reports that RNA exosome factors repress cryptic transcription (69).

Based on our findings that H3.3 interacts with Rpp29 (38) and that H3.3 depletion increases AS RNA (39), it is also possible that H3.3, itself, functions as an RNA-processing factor before nucleosome deposition. Indeed, there may be a regulatory dependence between RNA processing and H3.3 nucleosome assembly. Therefore, it is possible that chromatin assembly factor deletion up-regulates cryptic transcription by dysregulating both chromatin structure and RNA processing.

Genomic analyses indicate that most genes are overlapped by long noncoding RNAs that are expressed from either an upstream or an antisense promoter (70). These noncoding RNAs are thought to be alternative genetic information that regulates cellular responses to environmental and developmental stimuli (56, 68). This suggests that the signaling events that activate genes also make the cryptic promoters, contained within them, accessible to the transcription machinery. If noncoding RNA recruits H3.3 to these transcription units for deposition, it suggests a mechanism through which the information that they encode could be converted into epigenetically heritable chromatin structures. The finding that histone PTM enzymes, including the H3K36me3 methyltransferase Set2 (71, 72), also regulate cryptic transcription supports this hypothesis (70). This idea also suggests that the recruitment of H3.3 and Rpp29 to genes is a consequence of transcriptional activation and not an initiating event, which is consistent with our previous reports that H3.3 and Rpp29 begin to accumulate with RNA at the transgene array ~50 min after activation (38, 39). Importantly, noncoding RNAs also regulate PRC2 recruitment to its target genes (73). Therefore, elucidating the mechanisms through which noncoding RNA regulates H3.3 chromatin assembly could also provide new insight into PRC2 regulation and H3(K27M)-driven tumorigenesis (28–31).

Overall, our ChIP and qMS data suggest that Rpp29 restricts euchromatic PTMs and promotes heterochromatin PTM deposition. Specifically, by ChIP, we detected increases in the euchromatic PTMs, H3K36me3 and H3K4me3, and by qMS, we detected increases in the following H3 PTMs: K14ac, K27ac, K27me1, K36me2. The fact that Hira deletion does not affect H3K4me3 and H3K36me3 levels in mouse ESCs suggests that RII H3.3 chromatin assembly is not required for their deposition (7). Therefore, Rpp29 may indirectly repress euchromatic PTMs by repressing transcription. The finding that Rpp29 depletion decreases both H3K9me3 and H3K27me3 suggests that Rpp29 may also repress euchromatic PTMs by promoting heterochromatin PTM deposition.

Currently, we do not know the mechanism through which Rpp29 promotes H3K9me3 and H3K27me3. Because Rpp29 depletion increases K36me2, which is known to antagonize K27me3 (61, 62), Rpp29 could promote K27me3 by repressing H3 Lys-36 methylation. It has also been reported that RNA prevents PRC2 from binding to chromatin (74, 75). Therefore, as a component of an RNase P variant that regulates H3.3 deposition, Rpp29 could promote H3K27me3 by degrading RNAs that inhibit PRC2 targeting. This idea is consistent with our finding that the expression of exogenous Rpp29 accelerates RNA degradation and chromatin compaction at the activated transgene array (38). Alternatively, Rpp29 could process the noncoding RNAs that recruit PRC2 to its target sites through an unknown mechanism (73). At this time, we also do not know whether the effects of Rpp29 depletion on histone PTMs precede or follow changes in transcription.

The finding that Rpp29 levels impact histone PTM regulation and gene expression has important implications for disease processes. Rpp29 (i.e. POP4) is overexpressed in ovarian and breast tumors with 19q12 amplifications (76, 77) and depleted in oligodendrogliomas with 1p/19q co-deletions (78). Therefore, Rpp29 copy number changes could promote tumorigenesis by altering the epigenetic inheritance of transcriptional programs. Of interest, the RNase MRP catalytic RNA, RMRP, is required for differentiation of T helper 17 (T17) lymphocytes, which indicates that it plays a role in tissue-specific transcriptional regulation (79). Like Rpp29, RMRP is also amplified in cancers, including glioma (80), breast (81), lung (82), prostate...
Rpp29 regulates H3.3 through transcriptional mechanisms

(83), and gastric tumors (84). If RMRP is a component of an RNase P variant that regulates H3.3 deposition, its overexpression could drive tumorigenesis by dysregulating epigenetic mechanisms.

We also found that the oncogenic H3.3 mutations impact the Rpp29–H3.3 interaction. Several, including the GCTB mutation, G34W, increase the affinity for Rpp29. Of interest, H3.3(G34W) has been reported to down-regulate transcription and increase chromatin compaction (40). Because we show that Rpp29 promotes heterochromatic PTM deposition, it is possible that H3.3(G34W) promotes tumorigenesis by enhancing the gene-silencing function of Rpp29. It is also interesting to note that RNase P and RNase MRP subunits, as well as H3.3 in GCTB, are mutated in diseases that originate in the metaphyseal region of bones (85). The recessive inheritance of mutations in RMRP causes cartilage hair hypoplasia, which is characterized by short stature due to impaired bone growth (86). The protein subunit, POP1, is also mutated in skeletal dysplasias (87–89). Therefore, it will be interesting to determine whether H3.3 and these RNase P factors regulate the same signaling events during bone development.

Finally, our analysis of PTM deposition on H3.3(G34V) revealed that this point mutation dysregulates the intramolecular modification of the Lys-27 and Lys-36 residues, consistent with a recent report examining the impact of G34L and G34W on these sites in cis (37). Specifically, we show that K27me1 and K27me2 are increased and K36me1 is decreased on H3.3(G34V) compared with WT. The requirement of PRC2 for all forms of H3K27 methylation (73) suggests that G34V, like K27M, may drive tumorigenesis by dysregulating PRC2 function (28–31). Importantly, H3K27me2 prevents the accumulation of H3K27me1 and H3K27ac, which are required for enhancer firing (90). Because enhancer activity is important for differentiation, it is possible that the persistence of K27me2 on H3.3(G34V) promotes tumorigenesis by preventing enhancer activation. Therefore, genome-wide analyses of K27me2 in tumor lines harboring the oncogenic Gly-34 mutations could identify dysregulated enhancers and genomic elements that cause differentiation to be blocked.

Taken together, our current and previous investigations of Rpp29- and H3.3-regulatory dynamics (38, 91) suggest that 1) H3.3 is recruited to its incorporation sites at transcriptionally active genes by noncoding RNA, and 2) Rpp29 represses transcription and H3.3 deposition and promotes H3.3-mediated epigenetic mechanisms by processing RNA transcribed from these sites through a currently unknown mechanism (Fig. 6D). Importantly, our results indicate that Rpp29 impacts the deposition of PTMs on the region of the H3.3 N-terminal tail that is a hot spot for oncogenic mutations (i.e. Lys-27, G34L/R/V/W, and Lys-36) (25). Although Rpp29 depletion did not alter Lys-27 and Lys-36 methylation on H3.3(G34V) in KNS42 cells, our finding that Rpp29 affects PTM deposition at Lys-27 and Lys-36, which surround it, suggests that G34V could impact Rpp29 function through a currently unknown mechanism. The requirement of H3.3 deposition for differentiation but not for basal transcription in mouse ESCs (7, 19, 24) suggests that the essential function of H3.3 in differentiation could be to convert the alternate genetic information encoded in the noncoding transcriptome into heritable gene expression programs through histone PTM deposition in partnership with a variant of RNase P that includes Rpp29.

Experimental procedures

Plasmids

H3.3-YFP, GST-H3.3-N-tail-αN-WT, GST-H3.3-N-tail-αN-4-PTM, YFP-Rpp29-C3, and pLKO were described previously (39, 92). The K27M, G34R, G34V, G34L, and G34A mutations were introduced into GST-H3.3-N-tail-αN and H3.3-YFP using the QuikChange site-directed mutagenesis kit (Agilent Technologies). The GST-H4 (1–48 aa), H2A (1–41 aa), and H2B (1–53 aa) constructs were created by cloning PCR products into pGEX-4T3 vector (SalI/EcoRI). Rpp29 was made shRNA-resistant using the QuikChange site-directed mutagenesis kit (Agilent Technologies), and full-length and Rpp29(75–220) were subjected to PCR and cloned into pCMV-FLAG vector (HindIII/BamHI).

Cell culture and transfections

KNS42 cells (35) (gift of Lynn Bjerke and Chris Jones, Institute of Cancer Research, Sutton, Surrey, UK) were grown in Dulbecco’s modified Eagle’s medium/F-12 medium supplemented with 10% FBS (Atlanta Biologics Ltd.). U2OS cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS and 1 mM penicillin/streptomycin (Thermo Fisher Scientific). Transfections for binding assays in U2OS cells were carried out by electroporation or lentiviral infection. OVCAR-3 cells were grown in RPMI 1640 medium supplemented with 10% FBS and 1 mM penicillin/streptomycin.

Knockdown analyses

Knockdowns were done using the following shRNAs (Sigma): shPop4 (Rpp29) (TRCN0000049878), shRpp20 (TRCN0000049859), and shHIRA (TRCN0000020518). Lentiviruses were prepared in 293-T cells as described previously (93). Briefly, 1 × 10⁶ cells were plated in 10-cm dishes, and cells were infected the next day with virus. At 24 h postinfection, cells were split into 10-cm dishes (1:3). At 48 h, puromycin was added (0.5 μg/ml). At 120 h, cells were harvested for RNA analysis or ChIP.

GST-binding assay

The assay was performed as described previously (38). Briefly, bacterially expressed GST-tagged histones were bound to GSH-Superflow Resin (Clontech), equilibrated with resuspension buffer (25 mM Tris, pH 7.5, 0.5 mM KCl, 10% glycerol, 5 mM β-mercaptoethanol, phenylmethylsulfonyl fluoride), and incubated with precleared lysates of U2OS cells expressing YFP-Rpp29 constructs overnight (4°C) with rotation. The next day, beads were washed three times with resuspension buffer, heated (95°C) for 3 min in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1) and 3× loading dye (150 mM Tris-HCl, pH 6.8, 6% SDS, 30% glycerol, bromphenol blue, 3% β-mercaptoethanol), and immunoblotted.
Rpp29 regulates H3.3 through transcriptional mechanisms

Immunoblotting and densitometry analysis

The following antibodies were used: GFP (which also recognizes YFP) (1:1000; catalog no. 1181446001, Roche Applied Science); histone H3.3 (1:1000; catalog no. 09-838, EMD Millipore); histone H3 (1:3000; catalog no. ab1791, Abcam); MYCN (1:1000; catalog no. 9405S, Cell Signaling Technology, Danvers, MA); HIRA antibody (1:1000; catalog no. 12463, Cell Signaling Technology); Rpp29 antibody (1:500; catalog no. NB1-92281, Novus Biologicals); FLAG antibody (1:10,000; M2; Sigma-Aldrich); GAPDH (1:5000; catalog no. 2118S, Cell Signaling Technology). Measurements of band intensities from scanned images of immunoblots and colloidal blue (Thermo Fisher Scientific) stained gels were done using ImageJ software (version 1.48, National Institutes of Health, Bethesda, MD).

RT-PCR and quantitative PCR (qPCR) analyses

To collect RNA, cells were trypsinized, pelleted, and lysed in TRIzol (Life Technologies, Inc.). RNA was purified using the Direct-zol RNA mini prep kit (Zymo Research, Irvine CA). For RT-PCR and quantitative PCR (qPCR) analyses scientific stained gels were done using ImageJ software (version 1.48, National Institutes of Health, Bethesda, MD).

Histone sample preparation for qMS

Histone samples for qMS were prepared as described previously with minor modifications (97). Cells were resuspended in nuclear isolation buffer (15 mM Tris, pH 7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl₂, 1 mM CaCl₂, 250 mM sucrose, supplemented with 1 mM DTT, 500 µM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, 5 mM microcystin, and 10 mM sodium butyrate immediately before use) with 0.2% Nonidet P-40 and incubated on ice for 10 min. Nuclei were
pelleted at 3400 × g for 5 min at 4 °C and washed twice in nuclear isolation buffer without detergent. Histones were extracted with 0.4 n H2SO4 for 2–4 h at 4 °C, separated from insoluble debris by centrifugation as above, and precipitated overnight at 4 °C by the addition of trichloracetic acid to a final concentration of 25%. Histones were pelleted by centrifugation as above, washed sequentially in acetone plus 0.1% HCl and acetone, air-dried, and resuspended in 0.1 M ammonium bicarbonate for derivatization with propionic anhydride. To propionylate free lysine residues, 1 volume of propionic anhydride reagent (25% propionic anhydride in 2-propanol) was added to 2 volumes of histone sample (generally containing 5–20 μg of protein) and incubated at 37 °C for 15 min. The sample was then dried in a SpeedVac and derivatized once more before overnight digestion with trypsin (1:20 ratio by mass) at room temperature in 0.1 M ammonium bicarbonate. After digestion, histones were derivatized twice more to propionylate free N termini and then desalted with C18 Stage Tips before analysis by LC-MS/MS.

Mass spectrometry and data analysis

Histone peptides were analyzed by LC-MS/MS as follows. Peptides were separated on fused silica capillary columns (75-μm inner diameter × 15 cm), packed with C18 resin (3 μm ReproSil-Pur 120 C18-AQ, Dr. Maisch GmbH), via an EasyLC 1000 nano-LC system (Thermo Fisher Scientific). Solvents A and B were composed of 0.1% formic acid in water and 0.1% formic acid in acetonitrile, respectively. The chromatography gradient consisted of 2–28% solvent B over 45 min, 28–85% solvent B over 5 min, and 85% solvent B for 10 min at a flow rate of 300 nl/min. Peptides eluted directly into an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) running in data-independent acquisition (DIA) mode. Each instrument cycle began with a full MS precursor scan in the Orbitrap from 300 to 1100 m/z in positive profile mode at a resolution of 120,000, followed by eight DIA MS/MS scans in the ion trap (positive centroid mode with collision-induced dissociation fragmentation at 35% normalized collision energy) with isolation windows of 50 m/z increasing from 325 m/z to 675 m/z, a second full MS scan, and eight more DIA MS/MS scans centered on 725–1075 m/z. The mass range of the DIA scans varied slightly, beginning with 120–1500 m/z for the first DIA scan and ending with 295–1500 m/z for the final DIA scan. EpiProfile, a custom software algorithm written in Matlab, was used to extract chromatographic peak areas of the masses corresponding to the uniquely modified peptide species (98). For each peptide sequence, the relative abundance of a uniquely modified form was obtained by calculating its peak area as a proportion of the sum of the peak areas for all modified and unmodified forms of that peptide sequence.

References

1. Talbert, P. B., and Henikoff, S. (2017) Histone variants on the move: substrates for chromatin dynamics. Nat. Rev. Mol. Cell Biol. 18, 115–126 CrossRef Medline
2. Weinberg, D. N., Allis, C. D., and Lu, C. (2017) Oncogenic mechanisms of histone H3 mutations. Cold Spring Harb. Perspect. Med. 7, a026443 CrossRef Medline
3. Jin, C., Zang, C., Wei, G., Cui, K., Peng, W., Zhao, K., and Felsenfeld, G. (2009) H3.3/H2A.Z double variant-containing nucleosomes mark “nucleosome-free regions” of active promoters and other regulatory regions. Nat. Genet. 41, 941–945 CrossRef Medline
4. Mito, Y., Henikoff, J. G., and Henikoff, S. (2005) Genome-scale profiling of histone H3.3 replacement patterns. Nat. Genet. 37, 1090–1097 CrossRef Medline
5. Wirbelauer, C., Bell, O., and Schübeler, D. (2005) Variant histone H3.3 is deposited at sites of nucleosomal displacement throughout transcribed genes while active histone modifications show a promoter-proximal bias. Genes Dev. 19, 1761–1766 CrossRef Medline
6. Pechelintsev, N. A., McBryan, T., Rai, T. S., van Tuyn, J., Ray-Gallet, D., Almuozni, G., and Adams, P. D. (2013) Placing the HIRA histone chaperone complex in the chromatin landscape. Cell Rep. 3, 1012–1019 CrossRef Medline
7. Goldberg, A. D., Banaszynski, L. A., Noh, K. M., Lewis, P. W., Elsasser, S. J., Studer, S., Dewell, S., Law, M., Guo, X., Li, X., Wen, D., Chappier, A., DeKelver, R. C., Miller, J. C., Lee, Y. L., et al. (2010) Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell 140, 678–691 CrossRef Medline
8. Wong, L. H., Ren, H., Williams, E., McGhie, J., Ahn, S., Sim, M., Tam, A., Earle, E., Anderson, M. A., Mann, J., and Choo, K. H. (2009) Histone H3.3 incorporation provides a unique and functionally essential telomeric chromatin in embryonic stem cells. Genome Res. 19, 404–414 Medline
9. Drané, P., Ouararhni, K., Depaux, A., Shuaib, M., and Hamiche, A. (2010) The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes Dev. 24, 1253–1266 CrossRef Medline
10. Luijsterburg, M. S., de Kräger, I., Wieagnet, W. W., Shah, R. G., Smeenk, G., de Groot, A. J. L., Pines, A., Vertegaal, A. C. O., Jacobs, J. J. L., Shah, G. M., and van Attikum, H. (2016) PARP1 links CHD2-mediated chromatin expansion and H3.3 deposition to DNA repair by non-homologous end-joining. Mol. Cell 61, 547–562 CrossRef Medline
11. Frey, A., Listovsky, T., Guibaud, G., Sarkies, P., and Sale, J. E. (2014) Histone H3.3 is required to maintain replication fork progression after UV damage. Curr. Biol. 24, 2195–2201 CrossRef Medline
12. van der Heijden, G. W., Derijck, A. P., Posfai, E., Giele, M., Pelczar, P., Ramos, L., Wansink, D. G., van der Vlag, J., Peters, A. H., and de Boer, P. (2007) Chromosome-wide nucleosome replacement and H3.3 incorporation during mammalian meiotic sex chromosome inactivation. Nat. Genet. 39, 251–258 CrossRef Medline
13. Torres-Padilla, M. E., Bannister, A. J., Hurd, P. J., Kouzarides, T., and Zernicka-Goetz, M. (2006) Dynamic distribution of the replacement histone variant H3.3 in the mouse oocyte and preimplantation embryos. Int. J. Dev. Biol. 50, 455–461 Medline
14. Loppin, B., Bonnefoy, E., Anselme, C., Laurentson, A., Karr, T. L., and Couble, P. (2005) The histone H3.3 chaperone HIRA is essential for chromatin assembly in the male pronucleus. Nature 437, 1386–1390 CrossRef Medline
15. Voon, H. P., and Wong, L. H. (2016) New players in heterochromatin silencing: histone variant H3.3 and the ATRX/DAXX chaperone. Nucleic acids Res. 44, 1496–1501 CrossRef Medline
16. Wong, L. H., McGhie, J. D., Sim, M., Anderson, M. A., Ahn, S., Hannan, R. D., George, A. J., Morgan, K. A., Mann, J. R., and Choo, K. H. (2010)
ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. *Genome Res.* **20**, 351–360

17. Lewis, P. W., Elsasser, S. J., Noh, K. M., Stadler, S. C., and Allis, C. D. (2010) Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in regulation-independent chromatin assembly at telomeres. *Proc. Natl. Acad. Sci. U.S.A.* **107**, 14075–14080

18. Elsasser, S. J., Noh, K. M., Diaz, N., Allis, C. D., and Banaszynski, L. A. (2015) Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. *Nature* **524**, 240–244

19. Jang, C. W., Shibata, Y., Starmer, J. Y., and Magnuson, T. (2015) Histone H3.3 maintains genome integrity during mammalian development. *Genes Dev.* **29**, 1377–1392

20. Tagami, H., Ray-Gallet, D., Almouzni, G., and Nakatani, Y. (2004) Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. *Cell* **116**, 51–61

21. Kraushaar, D. C., Jin, W., Maunakea, A., Abraham, B., Ha, M., and Zhao, K. (2013) Genome-wide incorporation dynamics reveal distinct categories of turnover for the histone variant H3.3. *Genome Biol.* **14**, R121

22. Huang, C., Zhang, Z., Xu, M., Li, Y., Li, Z., Ma, Y., Cai, T., and Zhu, B. (2013) H3.3-H4 tetramer splitting events feature cell-type specific enhancers. *Plos Genet.* **9**, e1003558

23. Huang, C., and Zhu, B. (2014) H3.3 turnover: a mechanism to poise chromatin for transcription, or a response to open chromatin? *BioEssays* **36**, 579–584

24. Banaszynski, L. A., Wen, D., Dewell, S., Whitcomb, S. J., Lin, M., Diaz, N., Elsasser, S. J., Chappier, A., Goldberg, A. D., Canaani, E., Rafii, S., Zheng, D., and Allis, C. D. (2013) Hira-dependent histone H3.3 deposition facilitates PRC2 recruitment at developmental loci in ES cells. *Cell* **155**, 107–120

25. Lindroth, A. M., and Plass, C. (2013) Recurrent H3.3 alterations in childhood tumors. *Nat. Genet.* **45**, 1413–1414

26. Wu, G., Broniscer, M., McEchron, T. A., Lu, C., Paugh, B., Becher, O. J., and Allis, C. D. (2013) Distinct H3F3A and H3F3B driver mutations define chordroblastoma and giant cell tumor of bone. *Nat. Genet.* **45**, 1479–1482

27. Fang, D., Gan, H., Lee, J. H., Han, J., Wang, Z., Riester, S. M., Jin, L., Chen, J., Zhou, H., Wang, J., Zhang, H., Yang, N., Bradley, E. W., Ho, T. H., Rubin, B. P., et al. (2016) The histone H3.3K26M mutation reprograms the epigenome of chordroblastosmas. *Science* **352**, 1344–1348

28. Lu, C., Jain, S. U., Hoelder, D., Bechet, D., Molden, R. C., Ran, L., Murphy, D., Venneti, S., Hameed, M., Pawel, B. R., Wunder, J. S., Dickson, B. C., Lundgren, S. M., Jani, K. S., De Jay, N., et al. (2016) Histone H3K26 mutations promote sarcomagenesis through altered histone methylation landscape. *Science* **352**, 844–849

29. Bjerke, L., Mackay, A., Nandhabalan, M., Burford, A., Jury, A., Popov, S., Bax, D. A., Carvalho, D., Taylor, K. R., Vinci, M., Bajrami, I., McConnell, I. M., Lord, C. J., Reis, R. M., Hargrave, D., et al. (2013) Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. *Cancer Discov.* **3**, 512–519

30. Yadav, R. K., Jablonowski, C. M., Fernandez, A. G., Lowe, B. R., Henry, R. A., Finkelstein, D., Barnum, K. J., Pidoux, A. L., Kuo, Y. M., Huang, J., O’Connell, M. J., Andrews, A. J., Onar-Thomas, A., Allshire, R. C., and Partridge, J. F. (2017) Histone H3G34R mutation causes replication stress, homologous recombination defects and genomic instability in *S. pombe*. *Elfie* **6**, e27406

31. Shi, L., Shi, I., Shi, X., Li, W., and Wen, H. (2018) Histone H3.3 G34 Mutations alter histone H3K36 and H3K27 methylation in *cis*. *J. Mol. Biol.* **430**, 1562–1565

32. Newhart, A., Powers, S. L., Shastrula, P. K., Sierra, I., Joo, L. M., Hayden, J. E., Cohen, A. R., and Janicki, S. M. (2016) *RNAP* Protein subunit, Rpp29, represses histone H3.3 nucleosome deposition. *Mol. Biol. Cell* **27**, 1154–1169

33. Newhart, A., Rafalska-Metzcaif, I. U., Yang, T., Joo, L. M., Powers, S. L., Kosenkov, A. V., Lopez-Jones, M., Singer, R. H., Showe, L. C., Skordalakes, E., and Janicki, S. M. (2013) Single cell analysis of RNA-mediated histone H3.3 recruitment to a cytomegalovirus promoter-regulated transcription site. *J. Biol. Chem.* **288**, 19882–19899

34. Lim, J., Park, J. H., Baude, A., Yoo, Y., Lee, Y. K., Schmidt, C. R., Park, J. B., Fellenberg, J., Zustin, J., Haller, F., Krücken, I., Kang, H. G., Park, Y. J., Plass, C., and Lindroth, A. M. (2017) The histone variant H3.3 G34W substitution in giant cell tumor of the bone link chromatin and RNA processing. *Sci. Rep.* **7**, 13459

35. Gopalani, V., Jarrous, N., and Krasnikov, A. S. (2018) Chance and necessity in the evolution of RNA-P. *RNA* **24**, 1–5

36. Jarrous, N. (2017) Roles of RNA-P and its subunits. *Trends Genet.* **33**, 594–603

37. Reiner, R., Ben-Assouli, Y., Krllovetsky, L., and Jarrous, N. (2006) A role for the catalytic ribonucleoprotein RNA-P in RNA polymerase III transcription. *Genes Dev.* **20**, 1621–1635

38. Reiner, R., Krasnikov-Yoe, N., Dehtiar, Y., and Jarrous, N. (2008) Function and assembly of a chromatin-associated RNA-P that is required for efficient transcription by RNA polymerase I. *Plos One* **3**, e4072

39. Serruya, R., Orlovetska, N., Reiner, R., Dehtiar-Zilber, Y., Wesołowski, D., Altman, S., and Jarrous, N. (2015) Human RNA-P ribonucleoprotein is required for formation of initiation complexes of RNA polymerase III. *Nucleic Acids Res.* **43**, 5442–5450

40. Marvin, M. C., Clauer-Münster, S., Walker, S. C., Sarkeshik, A., Yates, J. R., 3rd, Steinmetz, L. M., and Engelke, D. R. (2011) Accumulation of noncoding RNA due to an RNase P defect in *Saccharomyces cerevisiae*. *RNA* **17**, 1441–1450

41. Molla-Herman, A., Vallés, A. M., Gamenz-Elbaz, C., Antoniwick, C., and Huynh, J. R. (2015) tRNA processing defects induce replication stress and Chk2-dependent disruption of piRNA transcription. *EMBO J.* **34**, 3009–3027

42. Abu-Zhayia, E. R., Khoury-Haddad, H., Guttmann-Raviv, N., Serruya, R., Jarrous, N., and Ayoub, N. (2017) A role of human RNA-P subunits, Rpp29 and Rpp21, in homology directed-repair of double-strand breaks. *Sci. Rep.* **7**, 1002
Rpp29 regulates H3.3 through transcriptional mechanisms

49. Li, X., and Tyler, J. K. (2016) Nucleosome disassembly during human non-homologous end joining followed by concerted HIRA- and CAF-1-dependent reassembly. *Elife* 5, e15129

50. Adam, S., Polo, S. E., and Almouzni, G. (2013) Transcription recovery after DNA damage requires chromatin priming by the H3.3 histone chaperone HIRA. *Cell* 155, 94–106

51. Jones, J. M., Bhattacharya, A., Simkus, C., Vallieres, B., Veenstra, T. D., and Zhou, M. (2011) The RAG1 V(D)J recombination/ubiquitin ligase promotes ubiquitylation of acetylated, phosphorylated histone 3.3. *Immunol. Lett.* 136, 156–162

52. Lin, C. J., Koh, F. M., Wong, P., Conti, M., and Ramalho-Santos, M. (2014) Hira-mediated H3.3 incorporation is required for DNA replication and ribosomal RNA transcription in the mouse zygote. *Dev. Cell* 30, 268–279

53. Jullien, J., Astrand, C., Szenker, E., Garrett, N., Almouzni, G., and Gurdon, J. B. (2012) HIRA dependent H3.3 deposition is required for transcriptional reprogramming following nuclear transfer to Xenopus oocytes. *Epigenetics Chromatin* 5, 17

54. Ahmad, K., and Henikoff, S. (2002) The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. *Mol. Cell* 9, 1191–1200

55. Silva, A. C., Xu, X., Kim, H. S., Tjian, R., and Allis, C. D. (2007) Methylation of lysine 36 suppresses histone exchange on transcribed genes. *PLoS Biol.* 6, e277

56. Ruthenburg, A. J., Allis, C. D., and Wysocka, J. (2007) Examining histone posttranslational modifications from within coding regions through out the *Saccharomyces cerevisiae* genome. *PLoS Biol.* 6, e285

57. Venkatesh, S., Garcia, B. A. (2012) Recurrent and functional regulatory mutations in breast cancer. *Nature* 489, 452–455

58. Davidovich, C., and Cech, T. R. (2015) The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2. *RNA* 21, 2007–2022

59. Wang, X., Paucek, R. D., Gooding, A. R., Brown, Z. Z., Ge, E. J., Muir, T. W., and Cech, T. R. (2017) Molecular analysis of PRC2 recruitment to DNA in chromatin and its inhibition by RNA. *Nat. Struct. Mol. Biol.* 24, 1028–1038

60. Beltran, M., Yates, C. M., Skalska, L., Dawson, M., Reis, F. P., Yiiri, K., Fisher, C. L., Sibley, C. R., Foster, B. M., Bartke, T., Ule, J., and Jenner, R. G. (2016) The interaction of PRC2 with RNA or chromatin is mutually antagonistic. *Genome Res.* 26, 896–907

61. Natrajan, R., Mackay, A., Wilkerson, P. M., Lambrs, M. B., Wetskog, D., Arnedos, M., Shi, K. G., Kreyer, F. C., Langerod, A., Kreike, B., Reyal, F., Horlings, H. M., van de Vijver, M. J., Palacios, J., Weigt, B., and Reis-Filho, J. S. (2012) Functional characterization of the 19q12 amplicon in grade III breast cancers. *Breast Cancer Res.* 14, R53

62. Wreszczynska, K. O., Varadan, V., Byrnes, J., Lum, E., Kamalakaran, S., Levine, D. A., Dimitrova, N., Zhang, M. Q., and Lucito, R. (2011) Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. *PLoS One* 6, e28503

63. Ciecerealli, M., Barthel, F. P., Malta, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Ribo, M., Pagnotta, S. M., Anjium, S., Wang, J., Manyam, G., Zoppoli, P., Ling, S., et al. (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. *Cell* 164, 550–563

64. Huang, W., Thomas, B., Flynn, R. A., Gavzy, S. J., Wu, L., Kim, S. V., Hall, J. A., Miralid, E. R., Ng, C. P., Rigo, F. W., Meadows, S., Montoya, N. R., Herrera, N. G., Domingos, A. I., Rastinejad, F., et al. (2015) DDX5 and its associated lncRNA Rmrp modulate TH17 cell effector functions. *Nature* 528, 517–522

65. Feng, W., Li, L., Xu, X., Jiao, Y., and Du, W. (2017) Up-regulation of the long non-coding RNA RMRP contributes to glioma progression and promotes glioma cell proliferation and invasion. *Arch. Med. Sci.* 13, 1315–1321

66. Rheinbay, E., Parasuraman, P., Grimsby, J., Tiao, G., Engreitz, J. M., Kim, J., Lawrence, M. S., Taylor-Weiner, A., Rodriguez-Cuevas, S., Rosenberg, M., Hess, J., Stewart, C., Maruvka, Y. E., Stojanov, P., Cortes, M. L., et al. (2017) Recurrent and functional regulatory mutations in breast cancer. *Nature* 547, 55–60

67. Meng, Q., Ren, M., Li, Y., and Song, X. (2016) LncRNA-RMRP acts as an oncogene in lung cancer. *PLoS One* 11, e0164845

68. Park, J., and Jeong, S. (2015) Wnt activated β-catenin and YAP proteins enhance the expression of non-coding RNA component of RNase MRP in colon cancer cells. *Oncotarget* 6, 34668–34668

69. Song, H., Sun, W., Ye, G., Ding, X., Liu, Z., Zhang, S., Xia, T., Xiao, B., Xi, Y., and Guo, J. (2013) Long non-coding RNA expression profile in human gastric cancer and its clinical significances. *J. Transl. Med.* 11, 225

70. Futamura, N., Urakawa, H., Tsukushi, S., Arai, E., Kozawa, E., Ishiguro, N., and Nishida, Y. (2016) Giant cell tumor of bone arising in long bones possibly originates from the metaphyseal region. *Oncol. Lett.* 11, 2629–2634
86. Ridanpää, M., van Eenennaam, H., Chadwick, R., Johnson, C., Yuan, B., van Venrooij, W., Pruin, G., Salmela, R., Rockas, S., Mäkitie, O., Kaitila, I., and de la Chapelle, A. (2001) Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. Cell 104, 195–203 CrossRefMedline

87. Barraza-García, J., Rivera-Pedroza, C. L., Hisado-Oliva, A., Belinchón-Martínez, A., Sentchordi-Montane, L., Duncan, E. L., Clark, G. R., Del Pozo, A., Ibáñez-Garikano, K., Offiah, A., Prieto-Matos, P., Cormier-Daire, V., and Heath, K. E. (2017) Broadening the phenotypic spectrum of POP1-skeletal dysplasias: identification of POP1 mutations in a mild and severe skeletal dysplasia. Clin. Genet. 92, 91–98 CrossRefMedline

88. Elalaoui, S. C., Laarabi, F. Z., Mansouri, M., Mrani, N. A., Nishimura, G., and Sefiani, A. (2016) Further evidence of POP1 mutations as the cause of anauxetic dysplasia. Am. J. Med. Genet. A 170, 2462–2465 CrossRefMedline

89. Glazov, E. A., Zankl, A., Donskoi, M., Kenna, T. J., Thomas, G. P., Clark, G. R., Duncan, E. L., and Brown, M. A. (2011) Whole-exome re-sequencing in a family quartet identifies POP1 mutations as the cause of a novel skeletal dysplasia. PLoS Genet. 7, e1002027 CrossRefMedline

90. Ferenczy, M. W., Ranayhossaini, D. J., and Deluca, N. A. (2011) Activities of ICP0 involved in the reversal of silencing of quiescent herpes simplex virus 1. J. Virol. 85, 4993–5002 CrossRefMedline

91. Newhart, A., Negorev, D. G., Rafalska-Metcalf, I. U., Yang, T., Negorev, D. G., and Janicki, S. M. (2012) Single-cell analysis of Daxx and ATRX-dependent transcriptional repression. J. Cell Sci. 125, 5489–5501 CrossRefMedline

92. Everett, R. D., Parada, C., Grirpon, P., Sirma, H., and Orr, A. (2008) Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82, 2661–2672 CrossRefMedline

93. Ghoshal, K., Majumder, S., Datta, J., Motiwala, T., Bai, S., Sharma, S. M., Frankel, W., and Jacob, S. T. (2004) Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MBD2 in the suppression of rRNA gene expression. J. Biol. Chem. 279, 6783–6793 CrossRefMedline

94. Tanaka, Y., Okamoto, K., Teye, K., Umata, T., Yamagiwa, N., Suto, Y., Zhang, Y., and Tsuneoka, M. (2010) JmjC enzyme KDM2A is a regulator of rRNA transcription in response to starvation. EMBO J. 29, 1510–1522 CrossRefMedline

95. Gomez-Roman, N., Grandori, C., Eisenman, R. N., and White, R. J. (2003) Direct activation of RNA polymerase III transcription by c-Myc. Nature 421, 290–294 CrossRefMedline

96. Sidoli, S., and Garcia, B. A. (2017) Characterization of individual histone posttranslational modifications and their combinatorial patterns by mass spectrometry-based proteomics strategies. Methods Mol. Biol. 1528, 121–148 CrossRefMedline

97. Yuan, Z. F., Lin, S., Molden, R. C., Cao, X. J., Bhanu, N. V., Wang, X., Sidoli, S., Liu, S., and Garcia, B. A. (2015) EpiProfile quantifies histone peptides with modifications by extracting retention time and intensity in high-resolution mass spectra. Mol. Cell. Proteomics 14, 1696–1707 CrossRefMedline

Rpp29 regulates H3.3 through transcriptional mechanisms